GLP-1 mimetics and inhibitors of GLP-1 degradation (DPP4 inhibitors) are in widespread use for the treatment of type 2 diabetes, and GLP-1 mimetics are also licensed for the treatment of obesity [1]. The gene discussed is GLP1R; the disease is Obesity.